NPS Pharmaceuticals Inc., of Bedminster, N.J., reported findings from the Phase III REPLACE study of Natpara (recombinant human parathyroid hormone), showing that Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST